Summary
CVS Health Corporation (CVS) reported its 2025 fiscal year results, detailing a complex financial picture marked by revenue growth alongside significant operational challenges and strategic shifts. Total revenues increased by 7.8% to $402.1 billion, driven by growth across all segments, particularly in Health Care Benefits and Health Services. However, the company recorded a substantial $5.7 billion goodwill impairment charge related to its Health Care Delivery reporting unit within the Health Services segment, signaling significant valuation headwinds in that area. Furthermore, CVS Health faced substantial legal charges, including approximately $1.2 billion for legacy litigation and a $320 million charge for ongoing opioid litigation, which significantly impacted operating income. Despite these headwinds, the company generated $10.6 billion in net cash from operating activities, demonstrating strong cash flow generation. The company's Health Care Benefits segment saw a 9.7% increase in total revenues, largely due to growth in its government business, while the Health Services segment's adjusted operating income saw a slight decrease, impacted by client price improvements and higher medical benefit ratios in its healthcare delivery business. The Pharmacy & Consumer Wellness segment reported an 11.9% revenue increase, driven by pharmacy drug mix and increased prescription volume. The company ended the year with $8.5 billion in cash and cash equivalents, maintaining its dividend payout of $0.665 per share, reflecting a continued commitment to shareholder returns amidst a challenging operating environment.
Financial Highlights
55 data points| Revenue | $402.07B |
| Cost of Revenue | $221.17B |
| Gross Profit | $180.90B |
| Operating Expenses | $397.41B |
| Operating Income | $4.66B |
| Net Income | $1.77B |
| EPS (Basic) | $1.40 |
| EPS (Diluted) | $1.39 |
| Shares Outstanding (Basic) | 1.27B |
| Shares Outstanding (Diluted) | 1.27B |
Key Highlights
- 1Total revenues grew 7.8% to $402.1 billion, driven by robust performance across all operating segments.
- 2A significant $5.7 billion goodwill impairment charge was recorded for the Health Care Delivery reporting unit in the Health Services segment.
- 3CVS Health incurred substantial litigation charges totaling approximately $1.2 billion for legacy matters and $320 million for opioid litigation, significantly impacting operating income.
- 4Net cash provided by operating activities was strong at $10.6 billion.
- 5The Health Care Benefits segment's revenue increased by 9.7%, primarily driven by the government business.
- 6Pharmacy & Consumer Wellness segment revenue increased by 11.9%, boosted by pharmacy drug mix and increased prescription volume.
- 7The company maintained its quarterly cash dividend of $0.665 per share.